BLRX - BioLineRx Ltd.
After hours:
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.6200 |
| Open | 1.5900 |
| Bid | 1.6100 x 900 |
| Ask | 1.6700 x 1200 |
| Day's Range | 1.5900 - 1.6800 |
| 52 Week Range | 0.5500 - 1.9800 |
| Volume | |
| Avg. Volume | 506,771 |
| Market Cap | 102.141M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4600 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.67 |
Fair Value
Related Research
PR NewswireBioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported its unaudited financial results for the first quarter ended March 31, 2023, and provided corporate and portfolio updates.
PR NewswireBioLineRx to Report First Quarter 2023 Results on May 24, 2023
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today that it will release its unaudited financial results for the quarter ended March 31, 2023 on Wednesday, May 24, 2023, before the U.S. markets open.
InvestorPlace7 High-Potential Penny Stocks in the Biotech Sector
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ:AXSM), for example. At one time, it was a $2.50 stock. Now it’s up to $71 with a treatment for major depressive disorder. Fate Therapeutics (NASDAQ:FATE) once traded at less than $2.50, and ran to more than $114. Novavax (NASDAQ:NVAX) once traded around $3. All of them started small, but their strong pipelines didn’t let them stay cheap for long. In fact, find a biotech with
PR NewswireBioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). BioLineRx is now in compliance with all applicable listing standards and its American Depository Shares (ADSs) will continue to be listed and traded on the NASDAQ St
PR NewswireBioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced the publication of data from the Company's GENESIS Phase 3 clinical trial in the peer-reviewed journal Nature Medicine. The international GENESIS trial evaluated the safety and efficacy of the Company's lead investigational candidate motixafortide plus granulocyte colony-stimulating factor (G-CSF) versus placebo plus G-CSF for the mobilization of hematopoietic stem ce
InvestorPlaceThe 3 Best Biotech Stocks Under $1 to Buy for April
Typically, penny stocks are pure market wages for hardened gamblers. In fact, penny stocks are always risky — especially some of the best biotech stocks under $1 – and should oftentimes be avoided. And, as pointed out by the U.S. Securities and Exchange Commission (SEC), “Penny stocks may trade infrequently – which means that it may be difficult to sell penny stock shares once you have them. Because it may also be difficult to find quotations for penny stocks, they may be impossible to accuratel
Insider MonkeyBioLineRx Ltd. (NASDAQ:BLRX) Q4 2022 Earnings Call Transcript
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2022 Earnings Call Transcript March 22, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx 2022 Financial Results Conference Call. I would now like to turn over the call to John Lacey, Head of Investor Relations and Corporate Communications BioLineRx. Please go ahead. John Lacey: Thank […]
Zacks Small Cap ResearchBLRX: Confidence in a Strong Launch
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT 2022 Operational and Financial Results On March 22, 2023, BioLineRx Ltd. (NASDAQ:BLRX) reported 2022 operational and financial results in a press release concurrent with the filing of Form 20-F . A conference call and webcast were hosted later that morning. Key highlights since the previous earnings update in November
PR NewswireBioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported its audited 2022 annual financial results for the year ended December 31, 2022, and provided recent corporate and portfolio updates.
PR NewswireBioLineRx to Report 2022 Annual Financial Results on March 22, 2023
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today that it will release its audited financial results for the year ended December 31, 2022 on Wednesday, March 22, 2023, before the U.S. markets open.
PR NewswireBioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced a collaboration with Washington University School of Medicine in St. Louis to advance a Phase 1 clinical trial that will evaluate the safety and feasibility of the Company's lead clinical candidate motixafortide to mobilize CD34+ hematopoietic stem cells (HSCs) for gene therapies in sickle cell disease (SCD), one of the most common genetic diseases globally. Currently
PR NewswireBioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has appointed Tami Rachmilewitz, M.D., as Chief Medical Officer. Dr. Rachmilewitz will report to the CEO and lead the Company's clinical and medical functions. Her appointment is effective today, January 4, 2023.
BenzingaBioLineRx Highlights Early-Stage Trial Data From Cancer Vaccine Candidate
BioLineRx Ltd (NASDAQ: BLRX) announced results from the Phase 1/2a study of the intratumoral cancer vaccine candidate AGI-134 in patients with unresectable metastatic solid tumors. The study met its primary endpoint of AGI-134's safety and tolerability. In this first-in-human trial, 38 patients were treated with AGI-134. Part 1 demonstrated that AGI-134 was safe and well tolerated, with no dose-limiting toxicities reported. The maximum tolerated dose was not reached, and the recommended dose for
PR NewswireBioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced results from the Phase 1/2a study of intratumoral cancer vaccine candidate, AGI-134, designed to evaluate the safety and biological activity of AGI-134 in patients with unresectable metastatic solid tumors.
Zacks Small Cap ResearchBLRX: Self-Commercialization in the US
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT Third Quarter 2022 Operational and Financial Results On November 15, 2022, BioLineRx Ltd. (NASDAQ:BLRX) reported 3Q:22 operational and financial results in a press release concurrent with the filing of Form 6-K . A conference call and webcast were hosted later that morning. Key highlights since the previous earnings update
PR NewswireBioLineRx to Participate in the 12th Annual LifeSci Partners Corporate Access Event
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that management will participate in the 12th Annual LifeSci Partners Corporate Access Event, taking place January 9-11, 2023, in San Francisco, CA, and will be available for one-one-one meetings on January 11, 2023. Learn more about the event and schedule an in-person meeting with BioLineRx management here.
PR NewswireBioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported third quarter financial results and recent corporate and portfolio updates.
PR NewswireBioLineRx to Report Third Quarter 2022 Results on November 15, 2022
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended September 30, 2022 on Tuesday, November 15, 2022, before the U.S. markets open.
PR NewswireBioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and filed the Company's New Drug Application (NDA) for APHEXDA® (motixafortide) in stem cell mobilization for autologous transplantation in multiple myeloma patients. The FDA has assigned the NDA a Prescription Drug User Fee Act (PDUFA) target action date of September 9, 2023.
PR NewswireBioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq"). The letter notifies the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market, since the closing bid price for the Company's ADSs listed on Nasdaq was below USD $1.00 for 30 consecuti
PR NewswireBioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potential Motixafortide Indication Expansion in Gene Therapy at the 64th American Society of Hematology (ASH) Annual Meeting
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that its full pharmacoeconomic study that indirectly evaluated the cost-effectiveness of using the investigational drug motixafortide as a primary stem cell mobilization (SCM) agent in combination with granulocyte colony stimulating factor (G-CSF), against plerixafor in combination with G-CSF, in multiple myeloma (MM) patients undergoing autologous stem cell transplan
Zacks Small Cap ResearchBLRX: Cast Off the Bowlines: Aphexda Commercialization
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT Commercialization Plans for Motixafortide (APHEXDA®) BioLineRx Ltd. (NASDAQ:BLRX) submitted its New Drug Application (NDA) to the FDA on September 9, 2022 for Motixafortide (now branded Aphexda) in stem cell mobilization for multiple myeloma patients undergoing autologous bone marrow transplantation. Since then, BioLineRx
PR NewswireBioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced its U.S. commercialization plan for APHEXDA (Motixafortide) in stem cell mobilization for autologous bone marrow transplantation for multiple myeloma patients. If approved, the Company intends to commercialize APHEXDA in the U.S. independently in order to accelerate its availability to patients and to maximize the value of this innovative therapeutic candidate. To lea
PR NewswireBioLineRx Announces $15 Million Registered Direct Offering
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 13,636,365 of the Company's American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 13,636,365 ADSs, at a combined purchase price of $1.10 per ADS and associated warrant. Each ADS represents fifteen (
BenzingaBioLineRx Secures $40M In Debt Financing To Fund Commercialization Of Stem Cell Mobilization For Blood Cancer
BioLineRx Ltd (NASDAQ: BLRX) entered into a $40 million non-dilutive secured debt financing agreement with Kreos Capital. Per the terms of the agreement, the first tranche of $10 million was made available to BioLineRx upon execution of the definitive agreement. The remaining $30 million will be made available in two additional tranches subject to achieving pre-specified milestones. The tranches are available for drawdown at BioLineRx's discretion at various time points through October 1, 2024.